The stock will trade on PROACT 1 enrollment completion and the Q2 2027 topline readout timeline, not on quarterly financials. Monitor for any updates on the confirmatory full enrollment (~470 patients) expected in H2 2026 and any regulatory interactions that could derisk the accelerated approval pathway.
Drug in focus
PROK drug pipeline →REACT
● Neutral Named in this 8-K- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.
Price Chart
Executive Summary
ProKidney reported Q2 2026 results with no revenue or EPS surprises vs consensus, as the company remains a pre-commercial clinical-stage biotech. The key catalyst is the completion of enrollment for the PROACT 1 accelerated approval analysis (~320 patients), positioning the company for pivotal eGFR slope topline results in Q2 2027. Cash burn continues with $181.6M in cash supporting operations into mid-2027, and the net loss widened to $46.4M from $37.0M YoY.
Key Financial Metrics
Key Facts
- Completed enrollment of ~320 patients for the PROACT 1 accelerated approval efficacy analysis; pivotal topline results expected Q2 2027
- Cash, cash equivalents and marketable securities totaled $181.6M as of June 30, 2026, down from $224.9M at March 31, 2026
- Net loss before noncontrolling interest was $46.4M for Q2 2026 vs $37.0M for Q2 2025
- R&D expenses increased to $36.1M from $25.9M YoY, driven by PROACT 1 clinical costs
- Appointed Kenneth Locke as Chief Technical Officer in June 2026
Financial Impact
No revenue or EPS surprise; cash burn of ~$43M per quarter; cash runway into mid-2027
Risk Factors
- Clinical trial failure or negative eGFR slope results in Q2 2027
- Cash runway only into mid-2027, requiring future dilutive financing
- Regulatory risk: FDA may require additional studies before BLA acceptance
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-342397 |
| Document: prok-20260810.htm | 0001193125-26-342397 |
| Document: 0001193125-26-342397-index-headers.html | 0001193125-26-342397 |
| Document: 0001193125-26-342397-index.html | 0001193125-26-342397 |
| Document: 0001193125-26-342397.txt | 0001193125-26-342397 |
| 8-K Data (Synthetic) | 0001193125-26-342397 |
Track record
13 reports on PROK
5 of 5 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 5 of 5 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 Viewing No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers